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PERSPECTIVES IN CLINICAL NEPHROLOGY
Understanding the nature of renal disease progression
Among the several theories on the pathophysiology of progres-
sive nephropathies [1—41, the most convincing one [1, 2] suggests
that the initial reduction in nephron number progressively dam-
ages the remaining ones, which suffer the consequences of adap-
tive increases in glomerular pressure and flow. Glomerular capil-
lary hypertension is normally accompanied by enhanced
transglomerular protein traffic [5—7] and both are prevented in
experimental animals by a low protein diet or antihypertensive
drugs [6—10].
In the past the amount of protein found in the urine, taken as
an indicator of the underlying abnormality in glomerular perme-
ability, was considered by most nephrologists simply as a marker
of the severity of renal lesions. Today the results of many studies
[4, 11—14] indicate that proteins filtered through the glomerular
capillary may have intrinsic renal toxicity, which together with
other independent risk factors such as hypertension, can play a
contributory role in the progression of renal damage [reviewed in
15]. More proteins filtered through the capillary barrier means—
within certain limits—more proteins excreted in the urine.
If one believes in the intrinsic toxicity of filtered proteins,
urinary protein factored for creatinine excretion rate can become
a practical way of monitoring an individual patient's tendency to
progress. Treatments which simultaneously reduce urinary pro-
teins and the filtration fraction [16] are likely to have a beneficial
impact on the decline of the glomerular filtration rate (GFR) and
can be used to identify subcategories of patients with proteinuric
renal diseases whose tendency to progress can be limited by
therapeutic intervention.
According to the most widely used models of glomerular size
selectivity, the glomerular capillary can be considered as being
perforated by hypothetical cylindrical pores with different radii
[17, 18]. Different pore-size distribution probabilities have been
proposed so far as those that best replicate the curves of tracer
molecules used to predict the sieving coefficient of the membrane
in human glomerular diseases.
Enhanced transglomerular passage of dextrans in diabetes [19]
as well as in a number of different proteinuric conditions [re-
viewed in 20] defined the functional nature of glomerular perme-
ability defects in nephrotic patients and served to establish that
immune and non-immune mediated glomerular diseases with
massive proteinuria all share abnormalities in glomerular barrier
size-selective function. Compared to healthy subjects, nephrotics
have a substantial reduction in GFR and pore density, with a
smaller mean pore radius and an increase in the size of large
unselective pores.
Independently of the different structural components of the
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capillary that participate in the charge- and size-selective function
of the barrier, alterations in local hemodynamics play a decisive
role [20, 21] to the extent that acute increases in glomerular
capillary pressure were accompanied by a sudden impairment of
barrier size-selectivity in a model of renal vein obstruction [22]. In
another study aimed at mathematically dissociating hemodynam-
ics from the intrinsic permeability property of the membrane [231,
structural modifications of the barrier were required to explain
changes in dextran data obtained upon an increasing of glomer-
ular pressure in passive Heymann nephritis (PHN).
It thus appears that local generation of angiotensin II, possibly
formed in excessive amounts in response to hemodynamic injury
to the endothelium [24], shifts glomerular unselective pores
toward larger dimensions. There is now experimental and human
evidence that ACE inhibitors tend to enhance glomerular size
selectivity, but how they affect the functional properties of the
glomerular barrier remains speculative.
In a recent study in rats with spontaneous age-dependent
proteinuria [251 we found no differences in the morphometrical
parameters examined, including basement membrane thickness,
configuration of epithelial podocytes and frequency of epithelial
slit diaphragms, in untreated and ACE inhibitor treated animals
despite the fact that the latter had considerably less proteinuria.
These findings have been interpreted to indicate that the improve-
ment in the selective properties of the glomerular capillary wall
induced by the ACE inhibitor reflected differences in macromo-
lecular organization of the protein matrix in the GBM or in the
slit-diaphragm of the podocytes. This is consistent with recent
findings that ACE inhibitors reduce mRNA expression for extra-
cellular matrix components in experimental diabetes [26], as well
as in immunological models of massive proteinuria [27].
A 90 day course of enalapril given to humans with insulin-
dependent diabetes with nephropathy reduced systemic blood
pressure, lowered the fractional clearances of albumin and IgG,
and uniformly lowered the dextran sieving profile [28]. The
transmembrane dextran flux achieved during enalapril therapy
could only be explained by a reduction in the mean radius of the
functional pores perforating the glomerular capillary. In ten
patients with insulin-dependent diabetes and more severe renal
insufficiency a low dose of enalapril also lowered fractional
clearance of albumin and IgG and uniformly reduced the dextran
sieving profile over a wide range of molecular radii [29]. A
tendency towards a similar effect on the dextran sieving coefficient
was seen in patients with IgA nephropathy given enalapril, but
differences from baseline were significant only for very large
dextrans (more than 52 A in radius) [30].
It thus seems that ACE inhibitors in animals and humans
reduce the log-normal component of the assumed pore size
distribution [17] and, more importantly, cause the shunt-pathway
to become less prominent by reducing the radius of large unselec-
tive pores [21].
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Is progression of proteinuric renal disease to renal failure
related to glomerular ultrafiltration of proteins?
There is no question if one looks at the renal literature of the
last 20 years that in glomerular diseases more severe proteinuria
is associated with faster progression, and this correlation is even
stronger for patients with nephrotic-range proteinuria [31—38].
Thus, without any apparent relation with the initial diagnosis, 400
patients with non-diabetic proteinuric renal diseases had a low
tendency to progress if the urinary protein excretion rate was less
than 5 g/day, but tended to progress rapidly with higher rates [33].
Also, in insulin-dependent diabetes (IDD) the baseline urinary
albumin excretion rate correlated with declining GFR [39, 40]. A
similar correlation was found in 26 NIDD patients followed
prospectively for five years [41] and in 121 NIDD patients with
micro- and macroalbuminuria [42]. Even in so-called essential
hypertension, the onset of de novo proteinuria after a number of
years of adequate blood pressure control was a marker of
subsequent renal function decline [43].
That baseline proteinuria predicts a subsequent decline in renal
function is amply supported by the recently completed interim
analysis of the Ramipril Efficacy in Nephropathy (REIN) study
(Fig. 1). REIN is a randomized double-blind, placebo-controlled
multicenter clinical trial designed to investigate whether ACE
inhibitor therapy modifies the rate of GFR decline in patients with
non-diabetic proteinuric renal diseases [44]. The trial was de-
signed on the assumption that different degrees of protein traffic
through the glomeruli were associated with different rates of GFR
decline over time. Patients were therefore randomized at baseline
into two strata with urinary protein excretion rates of > 1
and < 3 (stratum 1) and  3 g/24 hr (stratum 2).
The first interim analysis so far, on 104 patients [45], found that
patients in stratum 1 were virtually non-progressing (—0.02 49
ml/mm/1.73 m2 month) while patients in stratum 2 had rapid GFR
decline, that is, —0.57 1.00 ml/mm/1.73 m2 month (P = 0.0001).
Overall, blood pressure control was no different in the two strata,
each comprising patients randomized to ramipril or conventional
therapy. A highly significant correlation (P = 0.016) has been
found between baseline urinary protein excretion and subsequent
GFR decline in all patients analyzed in the REIN study so far,
independently of the stratum and the assigned therapy.
Abnormal glomerular permeability to proteins, hormones and
growth factors causes proximal tubular cell dysfunction
As a consequence of abnormalities in glomerular barrier func-
tion, plasma proteins reach the tubular fluid and are extensively
handled by the proximal tubular epithelium. They are endocy-
tosed via clathrin-coated pits by a receptor-mediated or constitu-
tional pathway [46], and then degraded by lysosomes into the
constituent amino acids [47]. Proximal tubular cell reserve capac-
ity for this process is limited and increasing the protein load leads
to organelle congestion [48], lysosomal swelling and rupture,
eventually exposing cell cytoplasm and renal interstitium to the
injurious effect of lysosomal enzymes [49].
The case of transferrin is a good example. When transferrin
crosses the glomerular barrier in critical amounts the local acidic
pH of proximal tubular fluid favors iron release from the protein
that is continuously reabsorbed up to toxic concentrations [50].
Proximal tubular cells in culture loaded with transferrin-iron
present peroxidative damage to the cytosol and cell membrane,
reflected by an increase in lactate dehydrogenase (LDH) release
and malondialdehyde formation [51]. Part of the reabsorbed iron
is extruded by the cell back into the final urine. Hence, in
nephrotoxic serum nephritis the extent of tubulointerstitial injury
correlates with iron excretion in the urine [52]. In human condi-
tions associated with clinical proteinuria, such as diabetic ne-
phropathy, iron excretion in the urine is elevated as well [53] and
the activity of lysosomal enzymes in the proximal tubule is
enhanced [54].
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Urinary protein 1.39 0.58 3.4 0.47 6.74 2.04
excretion g/24 hours (1.0-2.5) (2.5-4.2) (4.2-14)
Rate of GFR decline 0.03 0.46 0.35 0.85* 0.60 1 .12**
ml/min/sqm/month
*p<0o5 (Middle vs. Lowest), ***p<002 (Highest vs. Lowest)
Fig. 1. Rate of GFR decline per tertiles of
baseline urinaiy protein excretion in 104 patients
with chronic renal disease and persistent
proteinuria followed for a median of 17.5
months (range 12 to 30).
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Another important point is that tubules express receptors for
hormones and growth factors, some of which are filtered as part of
non-selective proteinuria in a variety of glomerular diseases. For
example, in nephrotic animals and humans, urinary excretion of
the insulin-like growth factor I (IGF-I), a small peptide of 7600
Da that stimulates cell proliferation and extracellular matrix
deposition, is increased [55]. IGF-I in circulating blood is corn-
plexed to binding proteins to form complexes of 150 or 45 kDa
[56, 57]. There is experimental evidence that IGF-I undergoes
glomerular ultrafiltration in a molecular complex with those
proteins [58]. After filtration IGF-I dissociates from the binding
protein probably because of a reduction in intratubular pH as a
consequence of changes in the composition of tubular fluid.
Studies in vitro have shown that IGF-I in the ultrafiltrate retains
biological activity to the extent that incubation of mouse proximal
tubular cells, which express TGF-I receptors [59], with tubular
fluid from nephrotic rats increased the receptor p-subunit auto-
phosphorylation, indicating activation of IGF-I receptors. This is
in line with previous observations of changes in cultured proximal
tubule cell transport after binding of recombinant human IGF-I to
apical and basolateral membrane receptors [59, 60].
IGF-I is mitogenic for proximal tubular cells [61], as is the
tubular fluid from nephrotic rats that enhances 3H-thymidine
uptake when added to cultured cells [58], by a mechanism partially
prevented by neutralizing IGF-I receptor antibodies. IGF-I also
stimulates the synthesis of extracellular matrix components, which
may be relevant to its potential role in the development of
progressive tubulointerstitial damage associated with chronic gb-
merular diseases. Therefore, incubating mouse proximal tubular
cells with recombinant human IGF-I or urinary extracts from
nephrotic rats increased the synthesis of collagen type I and IV
from these cells [57]. In the presence of neutralizing IGF-l
receptor antibodies the cellular response to urinary tract was
markedly reduced.
Other investigators have demonstrated that IGF-I enhanced
the expression of TGF-f3 type II receptors without affecting
TGF-/3 production [62]. Since the TGF-/3ITGF-/3 receptor system
contributes to extracellular matrix accumulation in several renal
disease models, IGF-I, which reaches tubular cells with the
glomerular ultrafiltrate, may both directly and indirectly increase
collagen secretion by these cells.
Tubular protein overload up-regulates inflammatory and
vasoactive genes
In vitro, overloading proximal tubuli with albumin and other
proteins, with or without their lipid component, activates the
transcription of a number of genes encoding vasoactive and
inflammatory molecules, with potential toxic effects on the kidney.
Here we shall review the evidence (in vitro and in vivo when
available) that the phenotypic character of proximal tubular
epithelial cells may change in response to protein loading.
Monocyte chemoattractant protein-I and osteopontin
That excess proteins can induce chemokine gene expression has
been documented by findings that overloading of proximal tubular
cells in culture with albumin or transferrin-iron up-regulates the
monocyte chemoattractant protein-i (MCP-I) gene [631. This
appears to be implicated in changes in the proximal tubular cell
synthetic pathway that follow endocytosis of filtered proteins by
the tubuli [64]. MCP-1 is produced by monocytes [65] and by
many other cells including tubular epithelial cells [66]. Specifi-
cally, MCP-1 mRNA was induced in proximal tubular cells by
protein concentrations comparable to those found in proteinuric
urine [63]. Additional studies disclosed a unique pathway of signal
transduction independent of protein tyrosine kinase or protein
kinase [63].
Given the potent chemoattractive properties of MCP-l on
monocytes/macrophages and T lymphocytes [67, 68], it is tempting
to speculate that excessive proximal tubular cell synthesis under-
lies mononuclear cell migration [69, 70] into the interstitium.
In many cell types including renal mesangial [71] and glomer-
ular endothelial cells [72] MCP-1 gene expression depends on the
activity of the transcription factor nuclear factor kappa B (NFKB).
NFKB is present in the inactive form in the cytoplasm of most cells
and is activated upon proteolytic degradation of the inhibiting
subunit 1KB [73, 74]. The resulting NFKB dimer transbocates into
the nucleus and serves to activate transcription of interferons,
cytokines and cell adhesion molecules, all belonging to NFKB
target genes. In other cells [75] the transcription factor NFKB can
be induced by the stress caused by the accumulation of protein in
the cell endoplasmic reticulum. Congestion of the endoplasmic
reticulum with proteins may trigger NFKB activation through a
mechanism probably involving the production of oxygen radicals
[75].
Infected cells use a very similar mechanism as a fast and
effective antiviral response. Once a cell is infected by a virus its
protein synthesis machinery is induced to generate viral proteins
in large amounts, that accumulate the endoplasmic reticulum.
Organeile overload serves to up-regulate NFKB dependent genes
that form the antiviral molecule interferons and cytokines. Hence,
excess proteins in the proximal tubular epithelium up-regulate an
NFKB target gene, possibly indicating a more general mechanism
of tubular cell activation in response to protein stress [75].
Since in vitro experiments, although consistent, can only be
inferential and cannot be used to establish whether in vivo
glomerular protein traffic actually does modulate NFKB depen-
dent genes, in vivo evidence is essential for confirmation.
In rats with protein-overload proteinuria renal MCP-1 mRNA
levels were up-regulated and MCP-1 protein was mainly localized
in the tubules [76]. Another molecule with potent chemotactic
activity for monocytes [77] is osteopontin, a matrix glycoprotein
originally isolated from bone. Recent studies suggest a link
between osteopontin and interstitial infiltrate in animal models
including anti-Thy-I ncphritis, PHN and puromycin-induced ne-
phrosis [78, 791. Other findings are also potentially relevant to the
issue of protein over-reabsorption as a way to up-regulate genes
that may contribute to interstitial inflammation. Eddy and Giach-
clii found that early in the course of overload proteinuria in the
rat, osteopontin mRNA levels were elevated [761 in cortical
tubules. Interstitial monocytes were identified in the vicinity of the
osteopontin-positive tubules. These results suggest that in addi-
tion to MCP-1, osteopontin is another molecule that could start
initiating interstitial inflammation reaction, although no evidence
has yet been provided that proximal tubular cells secrete os-
teopontin into the interstitial space.
It is tempting to speculate that protein stress-induced NFKB
activation in proximal tubular cells up-regulates a number of
KB-dependent target chemokines and adhesion molecules that
mediate interstitial inflammation in many models of proteinuric
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glomerulopathies [80]. One such molecule might be RANTES, an
NFKB dependent chemokine [81] with potent chemotactic activity
for macrophages, granulocytes and T lymphocytes that is ex-
pressed by renal tubular cells [82].
Endothelin
Protein overload may theoretically up-regulate many NFKB-
dependent or independent genes potentially capable of triggering
an interstitial inflammatory reaction (Fig. 2). Recent studies
suggest a link between protein tubular reabsorption and increased
synthesis of endothelins, a family of vasoactive peptides. Endo-
thelins exist in three different isoforms [83], one of which, ET-1,
has been strongly implicated in disease progression [84—88]. It is
encoded by a single gene that contains cis-regulatory elements in
the 5'-flanking region including the TPA-responsive element,
nuclear factor 1 binding element and GATA motifs, necessary for
promoter function [89, 90]. After ET-1 binds to its receptor,
activation of protein kinase C stimulates the synthesis and rapid
dephosphoiylation of c-jun protein, which binds to a TPA-
responsive element inducing preproET-1 mRNA [91]. Within the
promoter region a novel AP-1 cis element has also been described
that mediates the induction of preproET-1 by fos and Jun tran-
scription factors [92].
Endothelins are generated by numerous cells in the kidney
including the tubules that secrete abundant amounts of ET-1 and
lesser amounts of ET-3 [93]. Epithelial cells of the deep medulla
generate more ET-1 than proximal cells [93]. Of particular
interest is the observation that most of the ET-1 released by the
medullary epithelium is found in the interstitium [91. Exposure of
proximal tubular cells in culture to increasing concentrations of
albumin induced a dose-dependent increase in the generation of
ET-1 [95]. Since delipidated albumin had the same effect on
tubular ET-1 synthesis, the lipid component of the protein
appears unlikely to be involved. Up-regulation of ET-1 synthesis
was not confined to albumin, but occurred when proximal tubular
cells were exposed to higher than normal concentrations of other
proteins such as IgG and transferrin [95] (Fig. 3). Thus, over-
reabsorption of albumin and other proteins may be one way of
up-regulating the tubular endothelin synthetic pathway.
In agreement with previous studies we found that enhanced
ET-1 in response to increasing concentrations of albumin was
mainly secreted toward the basolateral membrane of the cell [95].
Should this occur in vivo an excessive amount of ET-1 may
accumulate in the interstitial compartment with a number of
possible consequences. Preliminary studies indicate that ET-1
binds specifically to interstitial fibroblast receptors [96] and that
human interstitial fibroblasts exposed to ET-1 in vitro increase
their proliferation rate and actively synthesize extracellular matrix
proteins [96]. There also seems to be an amplification loop to
further enhance the ET-1 synthesis rate [971, to the extent that
fibronectin, collagen type IV and laminin added to cultured
tubular cells further induce ET-1 synthesis. ET-1 has chemotactic
properties on blood monocytes [98], and by binding to specific
receptors on monocytes/macrophages it induces the secretion of
proinfiammatory cytokines [99] that could theoretically further
contribute to the interstitial inflammatory reaction.
That enhanced renal synthesis of ET-1 does actually occur in
vivo in proteinuric progressive renal diseases has been convinc-
ingly documented in animal models. In the remnant kidney model
renal ET-1 gene expression and excretion of the corresponding
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Fig. 2. Schematic representation of the impact of increased glomerular
permeability to proteins on progressive renal damage. Protein overloading
induces a congestion of endolysosomes and endoplasmic reticulum in proxi-
mal tubular cells which may trigger activation of either NFKB dependent and
independent encoding chemokines, cytokines and endothelin (see test).
Excessive synthesis of inflammatoiy and vasoactive substances contribute to
fibroblast proliferation and interstitial inflammation.
peptide in the urine increased time-dependently after surgery and
correlated with the progression of renal damage [100]. In PHN,
urinary ET-1 also rose time-dependently and correlated with the
increase in urinary protein and renal structural damage [101].
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Fig. 3. Effect of exposure of proximal tubular cells in culture to increasing concentrations of proteins on ET-I generation. (A) Albumin, (B) IgG, (C)
transferrin. *P < 0.01 versus no protein added.
That up-regulation of the renal endothelin synthesis pathway
favors the development of renal lesions is suggested by studies in
transgenic animals. Mice overexpressing human ET-1 promoter
[1021 form more ET-1 in their kidneys and have renal lesions.
Furthermore, rats transgenic for the human ET-2 gene, which did
not develop hypertension, were phenotypically characterized by
severe lesions including interstitial fibrosis [103]. An association
has been described between increased urinary excretion of ET-1
and renal damage in patients after unilateral nephrectomy [1041
and with chronic glomerulonephritis [105]. Immunohistochemical
localization of ET-1 in biopsies from children with nephrotic
syndrome revealed strong ET-1 immunostaining in tubules [106],
We used a model of chronic proteinuria, PHN [101], to
investigate the localization of excess endothelin in the kidney in
response to protein traffic and to clarify whether ET-1 synthesis
might be modulated by drugs that restore the selectivity of the
glomerular barrier [107]. In the kidneys of control rats there was
weak specific staining in glomeruli, proximal and distal tubuli
whereas staining for ET-1 was strong in rats with PHN, mainly in
the proximal tubules and around inflammatory cells in interstitial
areas. Rats with PHN chronically treated with an ACE inhibitor
and an angiotensin II receptor antagonist, a combined therapy
that totally prevented proteinuria and preserved renal structural
integrity [108], had ET-1 staining in the kidney comparable to
control animals [107].
Lipids and lipoproteins
The deleterious effects of glomerular macromolecule traffic and
proximal tubular reabsorption on the kidney are not only linked to
the protein component of the various molecules. Since the
majority of plasma fatty acids are bound to albumin by specific
high-affinity binding sites [109], proximal tubular cells together
with proteins also take up and metabolize various lipids. In
proteinuric conditions uptake and degradation of the fatty acids
bound to albumin by tubular epithelium appear to lead to their
accumulation in cytosol where they cause a toxic insult [110]. In
nephrotic rats urinary excretion of fatty acids, cholesterol, choles-
terol esters and phospholipids was much higher than in control
rats [111]. Lipids in the filtrate derived from fatty acids bound to
albumin and high-density lipoprotein. In rats with overload pro-
teinuria a potent, chemotactic lipid was isolated from urine [112],
which attracted monocytes but not neutrophils.
Consistent with the in vivo data, exposure of isolated proximal
tubules to albumin induced the release of a lipid factor chromato-
graphically indistiguishable from that isolated from proteinuric
urine [113]. This inflammatory lipid was not released after incu-
bation of proximal tubules with delipidated albumin, suggesting
that synthesis of this molecule is a consequence of tubular
metabolism of fatty acids bearing albumin. It has been proposed
that the lipid component of filtered lipoproteins favors interstitial
inflammation as a consequence of changes in the tubular epithe-
hal cell phenotype that occur during the metabolism of lipopro-
teins.
As an additional pathway of injury, one may perhaps consider
that enhanced urinary protein excretion in experimental and
human renal diseases is associated with a higher than normal
urinary ammonium excretion. This has been explained by findings
that metabolic degradation of filtered proteins by proximal tubuli
increases ammoniagenesis [114]. However, despite animal studies
linking excess ammonia production by the kidney with progressive
renal injury [115], the true relevance of such a mechanism of renal
damage is far from proven.
Protein traffic, interstitial infiltrates and declining GFR:
A paradigm in experimental and human proteinuric
glomerulopathies with one exception
A number of studies in the last ten years have indicated that in
human glomerular diseases the severity of proteinuria correlated
with tubulointerstitial infiltrates mainly comprising CD4 type
T-lymphocytes and monocytes. There is also evidence, albeit
controversial, that the degree of tubulointerstitial injury predicts
renal function decline better than the severity of glomerular
damage [116].
Why does interstitial inflammation develop in proteinuric
nephropathies? Clues from animal experiments
There are several possible explanations for the fact that pro-
teinuric renal diseases are accompanied by tubulointerstitial le-
sions. One implies that interstitial inflammation is a reaction to
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the ischemic obliteration of peritubular capillaries that follows
obsolescence of the glomerular tuft [117, 118]. Alternatively,
interstitial inflammation may reflect the response of tubulointer-
stitial structures to protein overload through the mechanisms
discussed above.
Here, however, a major issue to be taken into account is that in
immune glomerulonephritis, as opposed to non-immune forms,
the immunological process can itself cause interstitial nephritis.
Therefore, renal proximal tubular cells present foreign and in
certain conditions even self antigens to infiltrating T-lymphocytes.
This certainly adds to the potential effect of protein overload in
causing interstitial inflammation in these diseases. That the two
mechanisms may synergize is sustained by the example of Hey-
mann's nephritis in the rat, the experimental counterpart of
human membranous nephropathy. In this model persistent pro-
teinuria is followed by a tubulointersitial inflammatory reaction,
which manifests after immune complexes are cleared from the
circulation [119], and maneuvers that limit proteinuria also pre-
vent tubulointerstitial nephritis. Thus, animals on dietary protein
restriction given an ACE inhibitor [120] reduce their urinary
protein excretion rate and the excretion of lysozyme in the urine,
which despite several limitations remains one of the most sensitive
markers of tubular injury [121]. In the nephrosis induced by
puromycin aminonucleoside, the acute phase of nephrotic syn-
drome is accompanied by an acute tubulointerstitial inflammatory
reaction [122, 123]. In the chronic phase of the disease, weeks
after the initial insult, proteinuria and tubulointerstitial lesions
again develop in close association and both can be substantially
prevented by ACE inhibitors [123]. In rats that develop protein-
uria and renal damage with aging a low-protein diet, by reducing
proteinuria, considerably limited interstitial inflammation [124].
The most convincing experimental evidence that proteins leak-
ing into the urinary space serve to trigger tubulointerstitial
inflammation has been provided by models of overload protein-
uria [69]. Rats injected with bovine serum albumin develop
massive proteinuria followed by heavy infiltrations of macro-
phages and lymphocytes into the renal interstitium. Unlike in
many other models of glomerulopathies, in overload proteinuria
interstitial injury cannot be attributed to an underlying immune
reaction, as it occurs in the majority of glomerular diseases, and
does not seem secondary to ischemia, at least within the limits of
light microscopy findings [69]. On the other hand, early changes in
the tubular epithelial cell cytoskeleton in these models suggest the
interstitial inflammatory reaction is secondary to tubular cell
injury, possibly driven by protein over-reabsorption.
Overload proteinuria can also be generated in rats by trans-
planting a pituitary tumor [12] that causes liver hyperplasia and
overproduction of albumin with consequent hyperalbuminuria. In
these animals proteinuria is invariably followed by tubulointersti-
tial inflammation and kidney enlargement, but T cell depletion,
while limiting interstitial inflammation, has rio effect on urinary
protein excretion. These findings indicate that at least in the
overload models the primary event subsequently leading to the
interstitial inflammatory reaction is probably the abnormal pro-
tein traffic.
The human counterpart
In humans focal and segmental glomeruloscierosis, IgA ne-
phropathy, membranous and mesangiocapillaiy glomerulopathy
and the nephropathy of systemic lupus, but also diabetic nephrop-
Table 1. Assessment of histological changes in minimal change
glomerulonephritis (MCGN) and in adriamycin nephrosis (ADR)
studied at days 20 to 30 from the onset of nephrotic proteinuria (data
are mean values of individual scores for each parameters)
GS PS PPD TPD C II IF
MCGN N = 6 0 1 0 0 0.3 0 0
ADR N = 6 0 1.3 0.3 0 0.6 0 0
Scores are: 1+, mild; 2+, moderate; 3+, severe. Abbreviations are: GS,
glomeruloscierosis; PS, podocyte swelling; PPD, podocyte protein drop-
lets; TPD, tubular protein droplets; C, casts; II, interstitial inflammation;
IF, interstitial fibrosis.
athy are consistently associated with interstitial mononuclear cell
infiltrates [125—129]. In all these conditions the degree of inter-
stitial damage indeed does correlate with the rate of renal
functional decline [130].
In 50 patients with chronic glomerulopathies [35] the degree of
tubulointerstitial injury predicted GFR decline. Several subse-
quent papers showed that chronic tubulointerstitial damage cor-
related with declining renal function in proteinuric non-diabetic
and diabetic nephropathies, as shown by careful histological
analyses [34, 36, 125, 126, 129]. Using a more sophisticated
approach Howie, Gunson and Sparke [131] found that the ratio of
brush border-positive to brush border-negative cells determined
by immunohistochemical staining was linearly correlated with the
reciprocal of serum creatinine. More light is cast on the sequence
of events from interstitial nephritis to renal failure by the serial
morphometry observation [132] that chronic tubulointerstitial
damage normally leads to tubular atrophy. With time this creates
a population of atubular glomeruli that precedes the formation of
interstitial fibrosis.
The case of minimal change
Minimal change glomerulopathy is a striking remarkable excep-
tion to the rule that interstitial infiltrates develop with time in
proteinuric glomerulopathies. It has to be considered, however,
that minimal change glomerulopathy has at least two features
which are at variance with the other forms of chronic proteinuric
nephropathies. First, for the duration of proteinuria, minimal
change is the only example of human proteinuric nephropathy
that, in a substantial percentage of patients, responds consistently
to steroids. Thus periods of elevated protein traffic excretion are
relatively limited in minimal change and this might not be enough
to generate the injury. To address this, we have formally com-
pared human and animal biopsies, taking advantage of adriamycin
nephrosis as one of the experimental models of epithelial cell
disease that best mimics the renal lesions in humans. Rats given a
single intravenous injection of adriamycin develop a nephrotic
syndrome with heavy proteinuria, hypoalbuminemia, and ultra-
structural abnormalities of the glomerular epithelial cells where
foot processes are lost and replaced by expanses of flattened
epithelium, as in human minimal change [133].
We compared biopsy findings in a group of patients with
minimal change nephropathy with renal specimens of rats with
adriamycin nephrosis. Both were studied between 20 and 30 days
from the onset of clinical symptoms attributable to the presence of
nephrotic proteinuria. Table 1 shows the results of the semiquan-
titative assessment of histological changes. At the time point
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Fig. 4. A. Kidney specimen from a patient with minimal change glomerulopathy taken three weeks after the onset of nephrotic proteinuria. No obvious
changes are present in the glomeruli, interstitium and tubules (Masson's trichrome X 100). B. Glomerulus at higher magnification from the same patients
affected by minimal change glomerulopathy showing the absence of significant changes (Masson's trichrome ><400). C. Kidney specimen from a rat 28
days after the injection of 7.5 mg/kg of adriamycin. No significant changes are detected in glomerular and tubulointerstitial structures (Masson's
trichrome). B. Glomerulus at higher magnification from the same rat treated with Adriamycin showing only a moderate swelling of podocytes (Masson's
trichrome x400). Reproduction of this figure in color was made possible by a grant from Hoechst Marion Roussel, Frankfurt, Germany.
considered both patients with minimal change nephropathy and
rats with adriamycin nephrosis showed rather slight changes
characterized by a mild to moderate swelling of glomerular
podocytes and by the presence of proteinaceous casts in some
distal tubules without evidence of glomerular sclerosis or intersti-
tial inflammation. Comparison of individuals scores performed
with Fisher Exact test did not show statistical significance for any
of the parameters used. The only difference observed between
minimal change and adriamycin nephrosis consisted in a slightly
more pronounced swelling of podocytes and in a higher number of
tubular casts in adriamycin nephrosis in which the defect in
glomerular permeability is in fact more severe. Figure 4 shows
representative findings of human and rat material taken at the
same time from the onset of nephrotic proteinuria. Considering
that adriamycin nephrosis is one of the most severe animal model
of nephrotic proteinuria that invariably progresses to tubulointer-
stitial damage and glomerulosclerosis, findings of rather mild
changes after 28 days give a quite precise indication of the time
necessary to develop inflammatory lesions and subsequent scle-
rosis. One has also to consider that minimal change nephrosis is
milder than adriamycin in its clinical expression and in these
patients a renal biopsy is almost invariably taken within two to
three weeks after the onset of nephrotic proteinuria. It is there-
fore not so surprising that early light microscopy findings in this
disease do not show interstitial inflammation.
The second argument that might explain the absence of inter-
stitial infiltrates in minimal change is possibly related to the
selectivity of proteinuria. In most cases of minimal change pro-
teinuria is highly selective and is normally constituted of albumin
and lower molecular weight proteins [134j. In vitro proteins larger
than albumin (such as IgG) alter expression of tubular activation
molecules even more than albumin itself. Therefore, it is possible
that chronic nephropathies with unselective proteinuria impact on
tubular activation and interstitial inflammation quite differently
than selective forms.
An additional issue that relates to the role of filtered comple-
ment might provide a partial explanation as to why selective
proteinuria does not necessarily lead to interstitial inflammation
as opposed to nonselective proteinuria. Actually, glomerular
lesions that cause unselective proteinuria normally allow comple-
ment component to enter the tubular fluid. Hence, the C5b-9
complex is found in the urine of a number of renal conditions
characterized by unselective proteinuria which include membra-
nous and diabetic nephropathies and focal glomerulosclerosis
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[135, 136]. A study has reported [137] that in the above conditions
the brush border of proximal tubules can potently activate com-
plement by the alternative pathway which determines cell injury
and interstitial inflammation.
Treatments that limit glomerular ultrafiltration of proteins
uniformly retard renal disease progression
Reducing the protein content in the diet
In rats with renal mass ablation [2, 138] as well as in animals
[139] with experimental diabetes and adriamycin nephropathy [8],
a low protein diet, by restoring the size-selective properties of the
glomerular barrier, prevented proteinuria and renal injury. Stud-
ies in humans with type I diabetes [140], and non-diabetic
proteinuric glomerulopathies [141, 1421 confirmed the beneficial
effect of a low-protein diet in reducing proteinuria and renal
function decline. Patients in whom the diet had less antiprotein-
uric effect were not protected from progressive renal damage. The
Modification of Diet and Renal Disease Study [143], investigating
the relations between proteinuria, prescribed and achieved blood
pressure, and decline in GFR, showed that baseline proteinuria
was a strong predictor of subsequent GFR decline. There was no
difference in the decline in GFR in patients with baseline protein-
uria less than 0.5 glday regardless of blood pressure control.
Additionally, lowering of blood pressure, particularly in patients
with > 3 g proteinuria, was associated with lessening proteinuria
during the first four months and in slowing the rate of GFR
decline in the long term [143]. These findings were interpreted by
the authors as supporting the suggestion that protein traffic
contributed pathogenetically to the progression of renal disease.
Lowering blood presence with ACE inhibitors
Beside a low protein diet antihypertensive drugs have been used
in animals and humans to retard renal disease progression.
Animal data. After the first report that in experimental diabetes
ACE inhibitors normalized glomerular hypertension and reduced
urinary proteins and renal injury better than conventional ther-
apy, studies in the remnant kidney, puromycin or adriamycin
nephropathies, in male MWF/Ztm rats, and more recently in
PHN, confirmed the antiproteinuric and renoprotective proper-
ties of ACE inhibitors [9, 101, 122, 144].
Human insulin dependent diabetes. In human IDD reduced
albumin excretion during the first year of treatment with meto-
prolol and furosemide [145] predicted a slower GFR decline in
the subsequent three years, and similar data have been obtained
with conventional antihypertensives in non-diabetic chronic renal
diseases, with a reduction in urinary albumin excretion rate again
predictive of slower GFR decline [16]. Subsequent studies showed
that at comparable blood pressure reduction ACE inhibitors
lowered proteinuria and the rate of GFR decline more effectively
than other antihypertensives [1461.
In a double-blind controlled trial of 409 patients with IDD [147]
captopril was better than conventional therapy in preserving renal
function and halved the need for dialysis and transplantation and
mortality at least in patients with baseline serum creatinine >1.5
ing/dI. Systemic blood pressure reduction was comparable in the
captopril and conventional therapy groups. By contrast, urinary
protein excretion rate declined early in the captopril group and
remained low thereafter but actually increased in the conventional
therapy group [148].
Beside protecting from GFR decline, the ACE inhibitor re-
duces microalbuminuria and delays progression to macroalbumin-
uria in incipient nephropathy [149]. A very recent trial in IDD
[150] found that over a two-year follow-up, microalbuminuric
controls had a progressive increase in albumin excretion rate
(11.8% per year), associated with declining GFR of about 4
ml/min/1.73 m2 per year. By contrast, captopril reduced the
albumin excretion rate by 17.9% per year and completely pre-
vented the decline in GFR. This was the first study showing that
ACE inhibitors do actually preserve renal function in IDD even at
the stage of microalbuminuria.
Human non-insulin dependent diabetes. Unlike IDD, there are
only few studies on the renoprotective effect of ACE inhibitors in
NIDD with overt nephropathy. In Pima Indians, who have high
incidence of NIDD, once clinical proteinuria is established GFR
starts to decline at a predictable linear rate of about 1 mI/mm per
month, despite good control of systemic blood pressure. A
three-year randomized controlled trial [42] showed a better
antiproteinuric effect and a slower rate of GFR decline with
enalapril than with conventional antihypertensive treatment in 46
NIDD patients with macroalbuminuria. In NIDD of Afro-Amer-
icans, ACE inhibitors were more antiproteinuric than conven-
tional therapy, including calcium channel blockers, and the rate of
GFR decline was slower than in the conventional therapy group
[151, 152].
A very recent trial in 94 normotensive NIDD patients with
microalbuminuria and normal renal function found that in over a
seven-year follow-up controls had progressive increases in albu-
min excretion rate (41% per year) and in serum creatinine (3.3%
per year) that were completely prevented in the enalapril group
[153]. The risk of progression to macroalbuminuria was 18% in
patients who received enalapril compared with 60% in those who
did not. These numbers are comparable with those reported in
IDD [149] and show that ACE inhibition can lower the overall risk
of progression from incipient to overt nephropathy by about 60%
to 70% in either IDD or NIDD.
Non-diabetic chronic nephropathies. A better effect of ACE
inhibitors on proteinuria accompanied by better preservation of
renal function was also documented in non-diabetic chronic
nephropathies [154 —157]. In a double-blind controlled trial of 583
patients with renal insufficiency caused by various disorders,
benazepril halved the overall risk of progressive renal insufficiency
(defined as doubling of baseline serum creatinine) over a three-
year follow-up [158]. The effect was greatest in patients with
glomerular disease and was related to the degree of baseline
proteinuria. As in Lewis's study [147], urinary protein excretion
rate decreased early (by about 30%) in the benazepril group and
remained low thereafter, but actually increased in the control
group. When adjustments were made for changes in blood
pressure, about 70% of the renoprotective effect of benazepril was
found to be independent of the antihypertensive action.
A recent meta-analysis of 41 studies on a total of 1124 patients,
558 of whom had non-diabetic renal disease, showed that at
comparable levels of systemic blood pressure reduction ACE
inhibitors lowered urinary proteins more than other antihyperten-
sive agents [159]. Whether this was the result of lowering glomer-
ular capillary pressure more [160] or of an additional effect of this
class of compounds on glomerular size-selective function is still a
matter of investigation [28, 301.
10 Remuzzi et al: Pathophysiology of progressive nephropathies
—100 —50 —20—16—12—8 —4 0 +4 +8+12+16
Change in GFR, %/year
Fig. 5. Meta-analysis of the effects of different classes of antihypertensives on
urinaty protein excretion and glomerular filtration rate in diabetic nephrop-
athy. Symbols are: (LI) diuretics and/or beta-blockers (N = 213); (•) ACE
inhibitors (N = 489); (0) nifedipine (N = 75); (0) calcium channel
blockers, except nifedipine (N = 63). Data are means and 95% confidence
intervals. N is the number of patients (figure modified from [1651).
The importance of target blood pressure. Recent studies showed
that systolic/diastolic blood pressure reduction to less than 130/80
mm Hg may even more effectively slow the progression of diabetic
[161] and non-diabetic renal disease [162]. This finding is consis-
tent with available evidence that either systolic [163] and diastolic
[1641 blood pressures are independent predictive factors for the
development of end-stage renal failure.
In the MDRD trial [162] of patients randomly assigned to the
usual or a low blood pressure goal, those in the latter group had
a substantially lower mean decline of GFR, which was more
evident in those with greater baseline proteinuria due to their
faster rate of renal function decline. In this trial, follow-up systolic
blood pressure was better predictive than diastolic of the rate of
decline of GFR. These findings led the authors to recommend a
blood pressure goal of 125/75 or less in patients with > 1 g/day
urinary proteins and 130/80 or less in those with proteinuria of
0.25 to 1 g/day. This study suggested for the first time that
different antihypertensives may equally reduce urinary protein
excretion and slow renal disease progression, provided tight
control of blood pressure (mean diastolic BP below 90 to 95 mm
Hg) is achieved and maintained. This conclusion was somewhat
biased by the fact that the lower blood pressure goal was achieved
by a more liberal prescription of ACE inhibitors (51% of patients
in the lower blood pressure group were given ACE inhibitors,
compared with 32% in the higher blood pressure group). Findings
that ACE inhibitors influenced proteinuria, blood pressure, and
rate of GFR decline could account, at least in part, for the better
renal protection in patients with a better blood pressure control.
The impression that the higher the effect of blood pressure
reduction, the less dependent is the antiproteinuric response on
the class of antihypertensive employed is corroborated by a very
recent meta-analysis [165] performed in human diabetic nephrop-
athy. This showed that ACE inhibitors are the only antihyperten-
sives that reduce proteinuria even with no changes in blood
pressure. These results are consistent with a previous meta-
analysis of more than 100 papers in human diabetes [166]. That
survey found that among antihypertensives only ACE inhibitors
consistently lowered urinary proteins, no matter the level of blood
ACEI CCC' Conventional Nifedipine
(N=72; n=1392)(N=18; n=r284) (N=24; n=307) (N=12; n=166)
) !!
Fig. 6. EJfrcts of different classes of antihypertensives on urinaty protein
excretion and mean arterial pressure. Data are weighted means and 95%
confidence intervals. Abbreviations are: ACEI, angiotensin converting
enzyme inhibitors; CCB, calcium channel blockers except nifedipine;
Conventional, beta blockers and/or diuretics; MAP, mean arterial pres-
sure; N, number of studies; n, number of patients (modified from [1651).
pressure reduction. By contrast, conventional therapy limited
proteinuria only when blood pressure was reduced more than 4%
[165].
In more general terms the effect of different drugs on urinary
proteins depends on the degree of blood pressure reduction
achieved. The antiproteinuric effect of ACE inhibitors appears
drug-specific rather than blood pressure-dependent. Therefore,
ACE inhibitors are superior to other agents for small reductions
in blood pressure, as in the case of normotensive or mildly
hypertensive patients. On the other hand, in severely hypertensive
patients both ACE inhibitors, and non-nifedipine calcium channel
blockers as well as other antihypertensives have a distinct anti-
proteinuric effect [167], which at least for ACE inhibitors is strictly
dependent on sodium restriction [168].
Overall, independently of the mechanism(s), whenever urinary
protein excretion is reduced (and whatever the drug is used) GFR
is protected from declining with time (Fig. 5) [165]. Non-nifedip-
me calcium channel blockers that had an antiproteinuric effect
comparable to that of ACE inhibitors also had a comparable
effect on the rate of GFR decline. On the other hand, conven-
tional antihypertensive therapy, which had less effect on urinary
protein excretion, was consistently less protective against the
decline in GFR (Fig. 5). In all the studies considered, nifedipine
uniformly failed to reduce urinary protein excretion (Figs. 5 and
6) and never influenced the rate of GFR decline, which actually
was faster than with placebo [165].
Taken together, the results of the studies mentioned in this
section appear consistent with the possibility that the renoprotec-
tive property of antihypertensives is in some sense driven by their
capacity to limit protein traffic.
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Summary
Animal and human proteinuric glomerulopathies evolve to
terminal renal failure by a process leading to progressive
parenchimal damage, which appears to be relatively independent
of the initial insult. Despite the fact that the mechanism(s) leading
to renal disease progression has been only partially clarified,
several studies have found that the amount of urinary proteins
(taken to reflect the degree of protein trafficking through the
glomerular capillary) correlated with the tendency of a given
disease to progress more than the underlying renal pathology. On
the other hand, dietary protein restriction and ACE inhibitors
were capable of limiting the progressive decline in GFR to the
extent that they could effectively lower the urinary protein excre-
tion rate. A constant feature of proteinuric nephritis is also the
concomitant presence of tubulointerstitial inflammation. So far it
was not clear if this is a reaction to the ischemic obliteration of
peritubular capillaries that follows glomerular obsolescence or
whether albumin and other proteins that accumulated in the
urinary space are indeed instrumental for the formation of the
interstitial inflammatory reaction. In recent years several studies
have convincingly documented that excessive and sustained pro-
tein trafficking could have an intrinsic renal toxicity. Here we have
reviewed the abundant evidence in the literature that the process
of reabsorption of filtered proteins activates the proximal tubular
epithelium. Biochemical events associated with tubular cell acti-
vation in response to protein stress include up-regulation of
inflammatory and vasoactive genes such as MCP-1 and endothe-
lins. The corresponding molecules formed in an excessive amount
by renal tubuli are secreted toward the basolateral compartment
of the cell and give rise to an inflammatory reaction that in most
forms of glomerulonephritis consistently precede renal scarring.
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